BRCA1 and breast carcinoma: Controlled ovarian stimulation seems to be safe and does not increase the baseline risk of neither ovarian nor breast cancer in patients harbouring BRCA1/2 mutations, especially when utilising stimulation protocols which uses letrozole to maintain physiological levels of oestrogen.